RankingsPricing
  1. US-listed companies
  2. VERTEX PHARMACEUTICALS INC
  3. Financials
  4. Net income margin (%)

VERTEX PHARMACEUTICALS INCVRTX

Market cap
$109.6B
P/E ratio
SummaryFinancials
Period EndNet income margin (%) YoY (%)
Dec 31, 2024-4.9-113.25%
Dec 31, 202336.7-1.40%
Dec 31, 202237.2+20.30%
Dec 31, 202130.9-29.24%
Dec 31, 202043.7+54.57%
Dec 31, 201928.3-58.91%
Dec 31, 201868.8+549.87%
Dec 31, 201710.6-314.46%
Dec 31, 2016-4.9-90.84%
Dec 31, 2015-53.9-57.65%
Dec 31, 2014-127.2+246.54%
Dec 31, 2013-36.7+996.54%
Dec 31, 2012-3.3-214.71%
Dec 31, 20112.9-100.55%
Dec 31, 2010-526.3

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)